RT Journal Article
SR Electronic
T1 Guideline adherence and cost of asthma treatment at emergency department
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1177
VO 44
IS Suppl 58
A1 Amer Khan
A1 Syed Azhar Sulaiman
A1 Azmi Ahmad Hassali
A1 Fahad Saleem
A1 Ahsan Aftab
A1 Irfhan Ali
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P1177.abstract
AB Objectives: To evaluate asthma guideline adherence (GINA 2011) at emergency department of Hospital Pulau Pinang, Malaysia and to calculate cost of adhered and non-adhered prescriptions.Method: A cross-sectional study was conducted at emergency department of Hospital Pulau Pinang, Malaysia. A total of 810 patient prescriptions of 27 doctors (30 prescriptions per doctor) were noted that were treated for acute asthma. Patients' prescriptions were categorized in terms of asthma severity. Prescriptions were labelled as adhered or non-adhered in terms of doctor treatment according to patient asthma severity as recommended by CPG (GINA 2011). Cost of adhered and non-adhered was calculated according to asthma severity.Results: Six hundred and twenty eight (77.5%) patients received guideline (GINA 2011) adhered pharmacotherapy. Six hundred and seventy eight (83.7%) patients asthma were classified as mild asthma, 128 (15.8%) patients were classified as moderate asthma and 4 (0.5%) patients were classified as severe asthma. Univariate analysis indicate that patients with age group 25-35years and with hypertension as co-morbidity received significantly better pharmacotherapy (p=0.04, p=0.03 respectively). Total cost of 628 adhered prescriptions was RM 7593.96 whereas cost of 182 non-adhered prescriptions was RM 2367.96. Cost of single mild asthma adhered prescription (RM 12) was less as compared to non adhered mild asthma prescription (RM 14.52).Conclusion: Guideline adherence by emergency doctors was good as majority of patients received guideline adhered pharmacotherapy. The study signifies cost effective guideline adhered pharmacotherapy can reduce economic burden related to asthma treatment.